From lok4@web-city.co.jp Wed Nov 18 19:25:34 1998
Return-Path: <lok4@web-city.co.jp>
Delivered-To: bguenter@hal.qcc.sk.ca
Received: (qmail 2741 invoked by alias); 18 Nov 1998 19:25:33 -0000
Delivered-To: bruce.guenter@qcc.sk.ca
Received: (qmail 2730 invoked from network); 18 Nov 1998 19:25:31 -0000
Received: from ns.redcross.ac.jp (210.162.198.250)
  by hal.qcc.sk.ca with SMTP; 18 Nov 1998 19:25:31 -0000
Date: Wed, 18 Nov 98 11:11:08 EST
From: lok4@web-city.co.jp
To: angel@worldnet.att.net
Subject: NLAB News Release
Message-ID: <19981110093369.TVA471825@gte.net>

Tuesday November 17, 1:05 pm Eastern Time

Company Press Release

NuOncology Labs Engages EBI Securities

VIRGINIA BEACH, Va.--(BUSINESS WIRE)--Nov. 17,
1998--NuOncology Labs Inc. (OTC BB:NLAB - news)
announced Tuesday that it has engaged EBI Securities
Corp. to provide consulting services and advice to 
NuOncology Labs concerning business and financial 
planning, corporate organization and structure, 
private and public equity and debt financing, 
acquisitions, mergers and other similar business 
combinations. 

EBI Securities, a wholly owned subsidiary of 
Eastbrokers International Incorporated [Nasdaq:EASEC 
- news], is headquartered in Rockville, Md. EBI has 
over 20 offices in the United States and 12 offices 
located throughout Central and Eastern Europe. 

NuOncology Labs Inc. participates in the multi-billion 
dollar cancer treatment research and clinical 
laboratories industries by supporting the research, 
development, testing and licensing of cancer treatments 
along with the delivery of predictive tests for the 
optimization of contemporary cancer treatment. 

Additional corporate and financial information 
regarding NuOncology Labs, Inc. is available through 
and contained in an information disclosure statement 
provided to brokers pursuant to Rule 15c2-11 of the
Securities Exchange Act of 1934 (the ``Act''). 

Note: Statements in this document that are not 
descriptions of historical facts are forward-looking 
and subject to risks and uncertainties. 

Actual results could differ materially from those 
currently anticipated due to a number of factors, 
including risks relating to the early state of 
products under development; uncertainties relating to 
clinical trials; dependence on third parties; future 
capital needs; and risks relating to the 
commercialization, if any, of the Company's proposed 
products (such as marketing, safety, regulatory, 
patent, product liability, supply, competition and 
other risks). 

NuOncology Labs Inc. trades on the OTC Electronic 
Bulletin Board under the symbol "NLAB".

More Quotes and News:

Eastbrokers International Inc (Nasdaq:EASEC - news)
NuOncology Labs Inc (OTC BB:NLAB - news)
Related News Categories: banking, medical/pharmaceutical

